Researchers from Innogene, a leading south Korean biotech company, have explored mitochondrial revitalization as a strategy to stimulate hair regrowth. the team developed the Mito-
Study Insights and Results
The Mito-Activator Complex drives mitochondrial activity in both dermal papilla and fibroblast cell types. As an inevitable result, adenosine triphosphate (ATP) output increases, along with gene expression connected to hair growth. Unlike popular hair loss drugs such as minoxidil (which increases blood flow) or finasteride (which targets hormone pathways), miac works by targeting how cells generate and use energy. Clinical application testing on humans revealed clear positive effects on hair growth, making MiAc an exciting next-step cosmetic active.
Emergence of Cellular Beauty Solutions
This research is part of a broader innovation movement known as “cellness.” Brands are introducing new products that harness bioactive ingredients to support the body’s functions on a molecular level. Cellness-inspired beauty formulas-such as serums, supplements, and creams-aim to deliver benefits deep within skin and hair, not just on the surface.
Hair care options shaped by cellness are being developed to restore and reinforce hair, not just mask imperfections. Backed by science,these developments answer growing consumer calls for visible,long-lasting results in personal grooming.
Biological Mechanisms Behind the Mito-Activator Complex
According to a lead scientist from the project, this unique mix of ingredients is designed to counter hair loss by increasing mitochondrial performance inside hair cells. unlike customary hair therapies that mainly boost circulation (as with minoxidil) or block certain hormones (as with finasteride), the MiAc complex activates energy metabolism within the cell.
Experiments in cell cultures confirmed increased mitochondrial activation by analyzing ATP levels and mitochondrial content. The trials also noted higher expression of genes linked to mitochondrial function, such as mitochondrial transcription factor A (TFAM), ATP synthase F1 subunit alpha (ATP5A1), and estrogen-related receptor alpha (ERRα).
TFAM supports the preservation and reading of mitochondrial DNA (mtDNA). ATP5A1 enhances the production of cellular energy by improving ATP synthesis. ERRα manages gene networks for energy production and the creation of new mitochondria.
impact on Cellular Structures Supporting Hair
The formula impacts human dermal papilla cells (hDPCs) and dermal fibroblasts (hDFs),which play key roles in hair growth and strength. Growth signals released by hDPCs aid the multiplication and specialization of hair matrix cells. Laboratory assays showed enhanced cell vitality and mitochondria activity in these cells when exposed to MiAc.
Dermal fibroblasts are necessary for forming hair follicles.Further tests identified increases in expression of genes and proteins associated with hair growth in these fibroblasts. these included vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), and hepatocyte growth factor (HGF).
VEGF supports hair retention by stimulating the formation of new capillaries around follicles, which lifts blood supply. IGF-1 drives cell growth and movement during hair follicle formation.HGF acts as a local hormone aiding in hair follicle and scalp health.
From Laboratory Research to Consumer Products
The team highlights the need to confirm that lab-based outcomes are replicated in real-world use.Already, the MiAc ingredient has been included in formulations tested by volunteers and compared to a placebo.these trials showed measurable improvements in hair growth.Products featuring this ingredient are now moving into commercial release and are available to consumers.
Advertising and Regulatory Compliance for Hair Growth Cosmetics
South korea prohibits cosmetic brands from directly promoting the molecular action of ingredients to consumers, aiming to prevent confusion between cosmetics and pharmaceuticals. As a result, marketing focuses on the superior performance of these formulas during human testing rather than laboratory claims. This rule applies to the company’s current cosmetic lines in distribution.
